Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    63,804.12
    -719.05 (-1.11%)
     
  • CMC Crypto 200

    1,328.19
    -68.34 (-4.90%)
     
  • S&P 500

    5,110.32
    +61.90 (+1.23%)
     
  • Dow

    38,296.45
    +210.65 (+0.55%)
     
  • Nasdaq

    15,963.05
    +351.29 (+2.25%)
     
  • Gold

    2,348.30
    +5.80 (+0.25%)
     
  • Crude Oil

    83.82
    +0.25 (+0.30%)
     
  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

How Pfizer Plans to Unlock Another Mass-Market Vaccine

As the first company to introduce a COVID-19 vaccine, pharmaceutical behemoth Pfizer (NYSE: PFE) experienced enormous windfalls by delivering primary and booster shots on a global scale. Now, Pfizer is developing a vaccine for another infectious disease with a wide-open market. Pfizer will invest about $95 million in specialty vaccine maker Valneva, based in France.